Domů › Nemalobuněčný plicní karcinom › Alabama › Birmingham
Klinické studie Nemalobuněčný plicní karcinom v Birmingham, AL
22 studií pro Nemalobuněčný plicní karcinom hledá účastníky v lokalitách v Birmingham a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Probíhá náborFáze 3
- Central Alabama Research ( Site 0108), Birmingham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Probíhá náborFáze 3
- Alabama Oncology, Birmingham
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Probíhá náborFáze 3
- Alabama Oncology, St Vincent's Birmingham, Birmingham
- Alabama Oncology, Brookwood, Birmingham
- Alabama Oncology, Princeton, Birmingham
- a dalších 5
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Probíhá náborFáze 2
- University of Alabama at Birmingham, Birmingham
Pan-tumor MRD Study
Probíhá náborObservační studie
- Alabama Oncology, Birmingham
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Probíhá náborFáze 1/2
- University of Alabama at Birmingham, Birmingham
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Probíhá náborFáze 3
- Local Institution - 0347, Birmingham
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Probíhá náborFáze 2/3
- Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology, Birmingham
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Probíhá náborFáze 1/2
- UAB Medicine - UAB Hospital, Birmingham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Probíhá náborObservační studie
- University of Alabama at Birmingham, Birmingham
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Probíhá náborFáze 1/2
- The University of Alabama, Birmingham
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Probíhá náborFáze 1/2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Probíhá náborFáze 1
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Probíhá náborFáze 1
- Uni of Alabama at Birmingham, Birmingham
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Probíhá náborFáze 1
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- a dalších 1
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Probíhá náborFáze 3
- Central Alabama Research, Birmingham
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
Probíhá náborFáze 2
- University of Alabama at Birmingham, Birmingham
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Probíhá náborFáze 2
- University of Alabama at Birmingham, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Probíhá nábor
- University of Alabama at Birmingham, Birmingham
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Probíhá náborFáze 2
- The University of Alabama at Birmingham Hospital, Birmingham
GEMINI-NSCLC: NSCLC Biomarker Study
Probíhá náborObservační studie
- Alabama Oncology, Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Probíhá náborObservační studie
- Massive Bio SYNERGY-AI site, Birmingham
Studie Nemalobuněčný plicní karcinom v jiných městech
- Houston, TX145 studií
- New York City, NY121 studií
- Arlington, VA104 studií
- Nashville, TN97 studií
- Boston, MA90 studií
- Los Angeles, CA87 studií
- St. Louis, MO73 studií
- Chicago, IL61 studií
- Baltimore, MD60 studií
- San Antonio, TX59 studií
- Columbus, OH57 studií
- Washington, DC55 studií
Další studie v Birmingham
- Rakovina (všechny typy)31 studií
- Rakovina prsu24 studií
- Rakovina vaječníků23 studií
- Obesity23 studií
- Akutní myeloidní leukemie21 studií
- Mnohočetný myelom18 studií
- CHOPN17 studií
- Kardiovaskulární onemocnění17 studií
- Diabetes mellitus 2. typu16 studií
- Rakovina endometria16 studií
- Nadváha16 studií
- Cystická fibróza16 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.